Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Clinical trial NCT00675441 · TERMINATED

Trial details

NCT number: NCT00675441
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Graft-versus-Host Disease

Start date: 2008-04-01
Primary completion: 2011-08-01
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.